Uso del hierro intravenoso en un hospital de día de aparato digestivo: indicaciones, dosificación y efectos adversos

Dosal, Angelina; Calvet, Xavier; Moreno, Laura; López, María Laura; Figuerola, Ariadna; Ruiz, Miquel Ángel Torres; Suarez, David L.; Gené, Emili; Miquel, Mireia; Villòria, Albert

doi:10.1016/j.gastrohep.2010.02.011

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It represents a strength because the estimated costs will probably reflect the actual situation in clinical practice. It can be seen as a limitation because the analysis was performed in a particular patient population, most of them of advanced age and suffering from a range of digestive diseases leading to iron deficiency [14]. The costs could be different in another setting such as, for example, monographic inflammatory bowel disease units where patients are younger and most of them are of working age, which increases work time losses and therefore non-medical direct costs.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies by our group have shown an extensive use of i.v. iron for indications such as chronic blood loss associated with liver disease or angiodysplasia [14]. The efficacy of intravenous iron (and specifically of, FCM in these indications remains to be determined.…”

Section: Discussionmentioning

confidence: 99%

“…Data on the number of infusions and the amount of iron administered per patient were collected. The full description of the series of patients has been published elsewhere [14]. Costs of drugs were obtained from the prices approved by the Spanish Agency for the Regulation of Drugs and Healthcare Products [15].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency

et al. 2012

Self Cite

View full text Add to dashboard Cite

ObjectiveIntravenous iron is widely used to treat iron deficiency in day-care units. Ferric carboxymaltose (FCM) allows administration of larger iron doses than iron sucrose (IS) in each infusion (1000 mg vs. 200 mg). As FCM reduces the number of infusions required but is more expensive, we performed a cost-minimization analysis to compare the cost impact of the two drugs.Materials and MethodsThe number of infusions and the iron dose of 111 consecutive patients who received intravenous iron at a gastrointestinal diseases day-care unit from 8/2007 to 7/2008 were retrospectively obtained. Costs of intravenous iron drugs were obtained from the Spanish regulatory agencies. The accounting department of the Hospital determined hospital direct and indirect costs for outpatient iron infusion. Non-hospital direct costs were calculated on the basis of patient interviews. In the pharmacoeconomic model, base case mean costs per patient were calculated for administering 1000 mg of iron per infusion using FCM or 200 mg using IS. Sensitivity analysis and Monte Carlo simulation were performed.ResultsUnder baseline assumptions, the estimated cost of iron infusion per patient and year was €304 for IS and €274 for FCM, a difference of €30 in favour of FCM. Adding non-hospital direct costs to the model increased the difference to €67 (€354 for IS vs. €287 for FCM). A Monte Carlo simulation taking into account non-hospital direct costs favoured the use of FCM in 97% of simulations.ConclusionIn this pharmacoeconomic analysis, FCM infusion reduced the costs of iron infusion at a gastrointestinal day-care unit.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%